Loading
Rinatabart sesutecan is a next-generation folate-receptor ADC with a topoisomerase payload that responds in both ovarian and endometrial cancer regardless of receptor level.
Genmab (via ProfoundBio, 2024). RAINFOL-01: ORR 55.6% in ovarian cancer at 120 mg/m² and 50% in heavily pretreated endometrial cancer at 100 mg/m², the latter earning Breakthrough Therapy designation. Phase 3 RAINFOL-02 versus chemotherapy in platinum-resistant ovarian cancer is enrolling. Neutropenia and anaemia are dose-limiting; ocular toxicity is minimal compared with mirvetuximab.
Anti-FRα IgG1 with a hydrophilic linker carrying exatecan; bystander killing extends activity to FRα-low tumours. Connects to Folate receptor alpha.
1.Binds folate receptor alpha on the tumour cell
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
Breakthrough Therapy designation, advanced endometrial cancer after PD-(L)1 and platinum source
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Rinatabart sesutecan" OR ABSTRACT:"Rinatabart sesutecan" OR TITLE:"Rina-S" OR ABSTRACT:"Rina-S" OR TITLE:"PRO1184" OR ABSTRACT:"PRO1184") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Rinatabart sesutecan, not a curated reading list.
Shares Sequence folate-receptor ADCs by payload class, Folate receptor alpha, Advanced or recurrent endometrial cancer, Platinum-resistant ovarian cancer.
Shares Folate receptor alpha, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Folate receptor alpha, Platinum-resistant ovarian cancer, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Folate receptor alpha, Platinum-resistant ovarian cancer, Endometrial cancer, Ovarian cancer.
Shares Platinum-resistant ovarian cancer, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Advanced or recurrent endometrial cancer, Topoisomerase-I inhibitors (and ADC payloads), Endometrial cancer, Antibody-drug conjugate (ADC).
Shares Folate receptor alpha, Endometrial cancer, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Platinum-resistant ovarian cancer, Topoisomerase-I inhibitors (and ADC payloads), Ovarian cancer.